Roche’s anti-TIGIT drug tiragolumab has failed a lung cancer ... of efficacy in a first-line NSCLC study. With the SKYSCAPER-6 result now in, Roche said it will “evaluate any relevant changes ...

Roche has acquired rights to an obesity therapy by Denmark's Zealand Pharma in a collaboration deal worth up to $5.3 billion, as the Swiss drugmaker seeks to boost its prospects in the booming ...

Swiss pharmaceutical giant Roche said Wednesday that it had struck a deal worth up to $5.3 billion to develop Zealand Pharma's obesity drug candidate.

Roche, which put billions on the line a year ago across several ADC pacts, kicked off 2025 by returning to Innovent Biologics ...

Roche’s shares have risen 30.6% year to date compared with the large ... Xolair is the only FDA-approved drug to reduce allergic reactions in children and adults with one or more food allergies.

Roche, which in late 2023 agreed to buy drug developer Carmot ... CEO says better early warning will help make banking safer 6:59 PM UTC · Updated ago Energycategory US natgas prices jump ...